ArticlePain research & management2026
The Specialized Proresolving Mediator Maresin 1 Alleviated Neuropathic Pain Exacerbated by High-Fat Diet via Regulating Neuroinflammation.
Article in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Specialized Proresolving Mediator Maresin 1 Alleviated Neuropathic Pain Exacerbated by High-Fat Diet via Regulating Neuroinflammation.Pain research & management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundClinical observations have suggested an association between a high-fat diet (HFD) and neuropathic pain (NP). Studies also revealed that maresin 1 (MaR1) can regulate macrophage phagocytosis, modulate tissue repair and inflammatory resolution, and influence the progression of NP. However, the specific regulatory mechanisms of MaR1 in HFD-induced NP remain unclear.
objectiveThe aim of this study is to explore the effect of MaR1 on neuroinflammation in mice with NP induced by an HFD.
methodsA tibial nerve crush model with a HFD was used to establish HFD-induced chronic pain. The paw withdrawal threshold (PWT), which reflects mechanical allodynia, was measured to evaluate changes in pain-related behavior. Immunofluorescence was used to detect the relative number of macrophages and microglia, and the expression of growth-associated protein 43 (GAP43), while qPCR was used to measure the levels of proinflammatory cytokines.
resultsHFD consumption exacerbates nerve injury-induced NP formation and upregulates GAP43 expression. Macrophage infiltration and proinflammatory cytokine expression were increased in the DRGs of HFD-induced nerve injury mice. Intrathecal injection of the specialized proresolving mediator MaR1 alleviated nerve injury-induced chronic pain and decreased GAP43 expression in HFD-fed mice. Furthermore, MaR1 decreased proinflammatory macrophage migration in the damaged tibial nerves and DRGs of HFD-induced nerve injury model mice.
conclusionsThe specialized proresolving mediator MaR1 can reduce neuroinflammation and GAP43 expression in the DRG and injured nerve fibers and alleviate NP in HFD-fed mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.